We are live on ! Find out more
FBRX icon

Forte Biosciences
FBRX

47 hedge funds and large institutions have $330M invested in Forte Biosciences in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

685% more capital invested

Capital invested by funds: $42.1M → $330M (+$288M)

400% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 5

74% more funds holding

Funds holding: 27 → 47 (+20)

1.36% more ownership

Funds ownership: 1.07% → 2.43% (+1.4%)

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

Holders
47
Holders Change
+20
Holders Change %
+74.07%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
9
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
+$77.9M
2
Franklin Resources
Franklin Resources
California
+$25.7M
3
Citadel Advisors
Citadel Advisors
Florida
+$9.03M
4
CS
Credit Suisse
Switzerland
+$4.79M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.77M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$16.2M
2
FAM
Fred Alger Management
New York
-$6.85M
3
BI
BVF Inc
California
-$5.34M
4
MA
MYDA Advisors
New York
-$159K
5
TAM
Tocqueville Asset Management
New York
-$58.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$504K -$12.6K -19 -4%
Morgan Stanley
27
Morgan Stanley
New York
$397K +$184K +278 +567%
TAM
28
Tocqueville Asset Management
New York
$388K -$58.3K -88 -22%
AC
29
Athanor Capital
New York
$311K +$170K +257 New
BCM
30
Bridgeway Capital Management
Texas
$307K +$168K +253 New
SSA
31
Schonfeld Strategic Advisors
New York
$237K +$130K +196 New
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$219K +$119K +180 New
State Street
33
State Street
Massachusetts
$201K +$110K +166 New
Bank of America
34
Bank of America
North Carolina
$187K +$98.1K +148 +2,114%
Deutsche Bank
35
Deutsche Bank
Germany
$152K -$5.97K -9 -7%
TRCT
36
Tower Research Capital (TRC)
New York
$97K +$30.5K +46 +135%
JP Morgan Chase
37
JP Morgan Chase
New York
$47K +$25.9K +39 New
UBS Group
38
UBS Group
Switzerland
$34K +$17.9K +27 New
TFM
39
TFC Financial Management
Massachusetts
$24K +$13.3K +20 New
LWCFA
40
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$9K – – –
Citigroup
41
Citigroup
New York
$6K -$1.33K -2 -29%
Osaic Holdings
42
Osaic Holdings
Arizona
$6K +$3.31K +5 New
Wells Fargo
43
Wells Fargo
California
$3K +$663 +1 +100%
Carson Wealth (CWM LLC)
44
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
PGAM
45
Princeton Global Asset Management
New Jersey
$2K +$663 +1 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$1K -$1.33K -2 -67%
FHA
47
Flagship Harbor Advisors
Massachusetts
$1K – – –
Acadian Asset Management
48
Acadian Asset Management
Massachusetts
– -$17K -47 Closed
EW
49
Evoke Wealth
California
– -$11K -29 Closed
Group One Trading
50
Group One Trading
Illinois
– -$2K -7 Closed
1
2
3

FBRX Hedge Fund Activity: Q3 2020 in Review

47 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2020, worth a combined $330M — up 685% from $42.1M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new FBRX positions and 5 closed out — a net gain of 20 holders — while 9 added to existing stakes and 9 trimmed.

The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $77.9M. The largest seller was OrbiMed, cutting an estimated $16.2M.

  • 47 institutional investors held Forte Biosciences (FBRX) as of Q3 2020, up from 27 in Q2 2020.
  • Funds reported $330M of Forte Biosciences stock for Q3 2020, up 685% quarter-over-quarter.
  • 25 funds opened new Forte Biosciences positions in Q3 2020 and 5 closed out, a net change of +20 holders.
  • The largest Forte Biosciences buyer in Q3 2020 was ArrowMark Colorado Holdings, an estimated $77.9M added.
  • The largest Forte Biosciences seller in Q3 2020 was OrbiMed, an estimated $16.2M sold.

Based on aggregated 13F filings for Q3 2020.